Ambrx Biopharma, Inc. - Common Stock (NY:AMAM)

N/A UNCHANGED

Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ambrx Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition ↗

February 26, 2024

Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount.

Via InvestorPlace

3 Stocks to Buy That Are Up 200% or More in 2024 ↗

February 23, 2024

Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays.

Via InvestorPlace

The 3 Biotech Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Via InvestorPlace

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

February 10, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Looking Into Ambrx Biopharma's Recent Short Interest ↗

January 29, 2024

Via Benzinga

Assessing Ambrx Biopharma: Insights From 7 Financial Analysts ↗

January 09, 2024

Via Benzinga

Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma ↗

January 08, 2024

Via Benzinga

Analyst Ratings for Ambrx Biopharma ↗

November 14, 2023

Via Benzinga

Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson ↗

January 27, 2024

These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?

Via The Motley Fool

Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval ↗

January 22, 2024

FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic...

Via Benzinga

Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions ↗

January 22, 2024

Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and...

Via Benzinga

Topics Lawsuit

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

January 16, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

January 10, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

Via FinancialNewsMedia

January 08, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

From FN Media Group LLC

Via GlobeNewswire

Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results ↗

January 08, 2024

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 37,596.43 while the NASDAQ rose 1.89% to 14,799.21. The...

Via Benzinga

Topics Stocks

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 08, 2024

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 08, 2024

Via Benzinga

Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher ↗

January 08, 2024

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded down 0.19% to 37,396.28 while the NASDAQ rose 1.20% to 14,698.88. The S&P 500...

Via Benzinga

Topics Stocks

Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today? ↗

January 08, 2024

With Johnson & Johnson buying out Ambrx Biopharma, the win-win deal boosted AMAM stock while better positioning J&J’s oncology unit.

Via InvestorPlace

Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal ↗

January 08, 2024

Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi

Via Benzinga

US Stocks Mixed; Nasdaq Jumps Over 100 Points ↗

January 08, 2024

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.45% to 37,296.85 while the NASDAQ rose...

Via Benzinga

Topics Stocks

J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value ↗

January 08, 2024

The year's biggest medical conference kicked off with a melee of buyout news.

Via Investor's Business Daily

AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders

January 08, 2024

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 08, 2024

Via Benzinga

Biggest Short Squeeze Stocks Of The Week: Biotech Stocks Dominate, A Bitcoin-Related Stock Moves Up Leaderboard ↗

November 06, 2023

Potential short squeeze plays gained steam in 2021, continued throughout 2022 and remained a focus of traders looking for the next big move. High short interest and steep borrowing costs are among the...

Via Benzinga

Biggest Short Squeeze Stocks Of The Week: Two Biotech Stocks Move Up To Top The List ↗

October 31, 2023

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.